These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20824460)

  • 21. [European incentives for orphan medicinal products].
    Enzmann H; Lütz J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Orphan drugs--medications for patients with rare diseases].
    Thielke D; Thyssen JP; Hansen BJ
    Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
    Winstone J; Chadda S; Ralston S; Sajosi P
    Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The EU as a Political Determinant of Global Health: The Case of Research and Development Incentives for Orphan Medicines and Biotechnology.
    Perehudoff K; Ippel KA
    J Health Polit Policy Law; 2024 Oct; 49(5):911-938. PubMed ID: 38567770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Issues surrounding orphan disease and orphan drug policies in Europe.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does orphan drug legislation really answer the needs of patients?
    Haffner ME; Torrent-Farnell J; Maher PD
    Lancet; 2008 Jun; 371(9629):2041-4. PubMed ID: 18555916
    [No Abstract]   [Full Text] [Related]  

  • 27. Transposition and implementation of EU rare disease policy in Eastern Europe.
    Pejcic AV; Iskrov G; Raycheva R; Stefanov R; Jakovljevic MM
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):557-566. PubMed ID: 28975845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EU orphan regulation--ten years of application.
    Michaux G
    Food Drug Law J; 2010; 65(4):639-69, i-ii. PubMed ID: 24479246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I; Breckenridge A
    Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A regulatory overview about rare diseases.
    Llinares J
    Adv Exp Med Biol; 2010; 686():193-207. PubMed ID: 20824447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Orphan Medicines for Pediatric Use: A Focus on the European Union.
    Bolislis WR; Corriol-Rohou S; Hill-Venning C; Hoogland H; Joos A; King D; Kitcatt V; Le Visage G; Kühler TC
    Clin Ther; 2019 Dec; 41(12):2630-2642. PubMed ID: 31704041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of 11 national policies for rare diseases in the context of key patient needs.
    Dharssi S; Wong-Rieger D; Harold M; Terry S
    Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Competing for public funding of medicines to treat rare disorders in New Zealand.
    Crausaz S
    Bull World Health Organ; 2015 Feb; 93(2):67. PubMed ID: 25883396
    [No Abstract]   [Full Text] [Related]  

  • 34. Legal instruments supporting the development of orphan medicinal products in the European Union.
    Miaskowska-Daszkiewicz K
    Acta Pol Pharm; 2014; 71(1):181-7. PubMed ID: 24779206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interoperability Architecture for a Paediatric Oncology European Reference Network.
    Nitzlnader M; Canete Nieto A; Ribelles AJ; Brunmair B; Ladenstein R; Schreier G
    Stud Health Technol Inform; 2016; 223():39-45. PubMed ID: 27139383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promoting the development of drugs against rare diseases: what more should be done?
    Westermark K; Llinares J
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):541-3. PubMed ID: 23186396
    [No Abstract]   [Full Text] [Related]  

  • 37. Rare diseases and orphan drugs: Latvian story.
    Logviss K; Krievins D; Purvina S
    Orphanet J Rare Dis; 2014 Sep; 9():147. PubMed ID: 25231378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.
    Gutierrez L; Patris J; Hutchings A; Cowell W
    Orphanet J Rare Dis; 2015 May; 10():53. PubMed ID: 25935555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The legal regulation of life cycle of orphan pharmaceuticals].
    Gildeyeva GN; Kartavtsova TV
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.